The significance of monoamine oxidase-A expression in high grade prostate cancer
- PMID: 18804811
- PMCID: PMC2743604
- DOI: 10.1016/j.juro.2008.07.019
The significance of monoamine oxidase-A expression in high grade prostate cancer
Abstract
Purpose: Gleason grade 4/5 prostate cancer is a determinant for recurrence following radical prostatectomy. Monoamine oxidase-A is over expressed in grade 4/5 compared to grade 3 cancer. Monoamine oxidase-A is also expressed by normal basal cells and in vitro studies suggest that its function is to repress secretory differentiation. Therefore, monoamine oxidase-A in grade 4/5 cancer might reflect dedifferentiation to a basal cell-like phenotype. We investigated whether monoamine oxidase-A expression correlates with another basal cell protein, CD44, in high grade cancer and whether either is associated with an aggressive phenotype.
Materials and methods: A total of 133 grade 4/5 archival cancers from a cohort previously used to evaluate the prognostic significance of histomorphological variables were scored for monoamine oxidase-A and CD44 immunohistochemical labeling. Spearman rank correlations of the proteins, and histomorphological and clinical variables were determined. The univariate and multivariate value of each variable as a determinant of biochemical recurrence was assessed by logistic regression.
Results: Monoamine oxidase-A expression correlated with CD44. Neither was prognostic for biochemical recurrence. However, monoamine oxidase-A expression positively correlated with preoperative serum prostate specific antigen and the percent of grade 4/5 cancer.
Conclusions: Concurrent expression of monoamine oxidase-A and CD44 suggests that grade 4/5 cancer may be basal cell-like in nature, despite the absence of other classic basal cell biomarkers such as cytokeratins 5 and 14, and p63. The correlation of monoamine oxidase-A expression with prostate specific antigen and the percent of grade 4/5 cancer suggests that monoamine oxidase-A may contribute to growth of high grade cancer and that antidepressant drugs that target monoamine oxidase-A may have applications in treating prostate cancer.
Figures

Similar articles
-
Percent prostate needle biopsy tissue with cancer is more predictive of biochemical failure or adverse pathology after radical prostatectomy than prostate specific antigen or Gleason score.J Urol. 2002 Feb;167(2 Pt 1):516-20. doi: 10.1016/S0022-5347(01)69076-1. J Urol. 2002. PMID: 11792909
-
Length of positive surgical margin after radical prostatectomy as a predictor of biochemical recurrence.J Urol. 2009 Jul;182(1):139-44. doi: 10.1016/j.juro.2009.02.139. Epub 2009 May 17. J Urol. 2009. PMID: 19450829
-
What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.J Urol. 2008 Nov;180(5):1980-4; discussion 1985. doi: 10.1016/j.juro.2008.07.031. Epub 2008 Sep 17. J Urol. 2008. PMID: 18801519 Free PMC article.
-
Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.Eur Urol. 1999;36(1):21-30. doi: 10.1159/000019922. Eur Urol. 1999. PMID: 10364651
-
Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.Urology. 1999 Sep;54(3):479-85. doi: 10.1016/s0090-4295(99)00202-2. Urology. 1999. PMID: 10475358 Clinical Trial.
Cited by
-
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer.Nat Commun. 2020 Jun 1;11(1):2689. doi: 10.1038/s41467-020-15396-5. Nat Commun. 2020. PMID: 32483206 Free PMC article.
-
Serotonin signalling in cancer: Emerging mechanisms and therapeutic opportunities.Clin Transl Med. 2024 Jul;14(7):e1750. doi: 10.1002/ctm2.1750. Clin Transl Med. 2024. PMID: 38943041 Free PMC article. Review.
-
Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.Thorac Cancer. 2020 Oct;11(10):2858-2866. doi: 10.1111/1759-7714.13617. Epub 2020 Sep 2. Thorac Cancer. 2020. PMID: 32875729 Free PMC article.
-
Loss of MAOA in epithelia inhibits adenocarcinoma development, cell proliferation and cancer stem cells in prostate.Oncogene. 2018 Sep;37(38):5175-5190. doi: 10.1038/s41388-018-0325-x. Epub 2018 May 29. Oncogene. 2018. PMID: 29844571 Free PMC article.
-
Genetic and Proteinic Linkage of MAO and COMT with Oral Potentially Malignant Disorders and Cancers of the Oral Cavity and Pharynx.Cancers (Basel). 2021 Jun 29;13(13):3268. doi: 10.3390/cancers13133268. Cancers (Basel). 2021. PMID: 34209963 Free PMC article.
References
-
- Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517. - PubMed
-
- Stamey TA, McNeal JE, Yemoto CM, Sigal BM, Johnstone IM. Biological determinants of cancer progression in men with prostate cancer. JAMA. 1999;281:1395. - PubMed
-
- Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous